Elranatamab for Treatment of Multiple Myeloma With Central Nervous Involvement Refractory to Other Interventions
{{output}}
Background: Plasma cell leukemia and central nervous system involvement are two poor prognostic factors in myeloma, and such patients are often excluded from clinical trials. ... ...